The US is the bigger Cardiovascular Health Supplements market: $2.9 Bn against $547 Mn in 2023, about 5.2 times as large.
China grows faster: 7.2% a year, against 3.7%. The gap still grows from $2.3 Bn to $3 Bn by 2033.
Clinical research: 100 active trials in the US, 17 in China.
| Measure |  US |  China |
|---|---|---|
| Market size, 2023 | $2.9 Bn | $547 Mn |
| Market size, 2033 projected | $4.1 Bn | $1.1 Bn |
| Growth a year (CAGR) | 3.7% | 7.2% |
| Money added, 2023–2033 | $1.3 Bn | $549 Mn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $8.36 | $0.39 |
| Active clinical trials | 100 | 17 |
| High blood pressure (ages 30–79) % of adults 30–79 (WHO) | 31.6 2019 | 27.3 2019 |
| Full report | US report | China report |
Year by year, 2023 to 2033
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Cardiovascular Health Supplements, US or China?
The US is the bigger Cardiovascular Health Supplements market: $2.9 Bn against $547 Mn in 2023, about 5.2 times as large.
Which grows faster in Cardiovascular Health Supplements, US or China?
China grows faster: 7.2% a year, against 3.7%. The gap still grows from $2.3 Bn to $3 Bn by 2033.
More Cardiovascular Health Supplements comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Health figures: WHO. Population: World Bank.